STOCK TITAN

SINTX TECHNOLOGIES SIGNIFICANTLY STRENGTHENS ITS ANTIPATHOGENIC PATENT PORTFOLIO

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
SINTX Technologies, Inc. (SINT) has been granted its sixth United States patent in the last year, all related to the antipathogenic properties of silicon nitride. The significance of the patents lies in their innovative approaches towards utilizing silicon nitride in a wide range of antipathogenic solutions, covering applications in agriculture, dentistry, medical implants, durable medical equipment, and personal protective equipment.
Positive
  • None.
Negative
  • None.

The recent patent grants to SINTX Technologies for their antipathogenic applications of silicon nitride represent a significant advancement within the biomedical materials field. The unique properties of silicon nitride, which include the ability to inactivate pathogens, are pivotal in the development of medical devices and implants that are less susceptible to infections. This is particularly relevant in the context of increasing concerns about antibiotic resistance and hospital-acquired infections.

The patents covering the integration of silicon nitride with polymers such as PMMA and PEEK suggest potential for creating more resilient surfaces in medical environments. These materials could reduce the risk of postoperative infections and improve patient outcomes. Moreover, the development of antipathogenic face masks could have implications for public health, especially in mitigating the spread of respiratory viruses.

From a medical research perspective, the commercialization of these patented technologies could lead to collaborations with healthcare providers and medical device manufacturers. It is important to monitor the clinical trials and real-world applications of these technologies to assess their efficacy and safety in various medical settings.

The acquisition of multiple patents in the United States and abroad underscores SINTX Technologies' strategic positioning within the advanced ceramics market. The versatility of silicon nitride's applications, from agriculture to personal protective equipment, expands the company's market potential and could attract a diverse customer base. The focus on antipathogenic properties aligns with current market trends prioritizing hygiene and safety, which have been amplified by the global pandemic.

As SINTX continues to secure intellectual property rights, it is building a robust portfolio that can serve as a competitive moat against other players in the industry. The pending patent applications in various global markets indicate an intention to scale operations and protect market share internationally. Investors should watch for partnerships and licensing agreements that may arise as SINTX leverages its patents for commercial gain.

It is also critical to evaluate the company's ability to capitalize on these patents through successful product development and market penetration. The impact on SINTX's financial performance will largely depend on the speed of commercialization and the adoption rate of their technologies in the market.

The legal landscape of patent protection plays a crucial role in the valuation and long-term sustainability of intellectual property for companies like SINTX Technologies. The issuance of six United States patents within a year is a testament to the company's innovation and its legal team's proficiency in navigating the patent system. The cross-jurisdictional patent protection, with three additional foreign patents granted, provides a layer of security for the company's technologies in major markets.

Understanding the scope and enforceability of these patents is essential. The patents must be robust enough to withstand challenges and potential litigation, which is common in the high-stakes arena of medical technology. The breadth of applications covered by these patents could also lead to strategic licensing opportunities, enabling SINTX to generate revenue streams without directly manufacturing all end-products.

For stakeholders, the effective management of these patents can lead to increased market share and a stronger negotiating position in collaborations and mergers. The legal strategy surrounding these patents will be influential in determining the company's future growth trajectory and market influence.

SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT; “SINTX” or the “Company”), a manufacturer and developer of advanced ceramic materials and related technologies, announced that it has been granted its sixth United States patent in the last year. All of these United States patents are related to the antipathogenic properties of silicon nitride.

The six United States patents granted to SINTX are:

  • 11,591,217; Antipathogenic Devices and Methods Thereof
  • 11,672,252; Antifungal Composites and Methods Thereof
  • 11,738,122; Antibacterial Biomedical Implants and Associated Materials, Apparatus, and Methods
  • 11,844,344; Systems and Methods for Rapid Inactivation of SARS-COV-2 by Silicon Nitride and Aluminum Nitride
  • 11,850,214; Antiviral Compositions and Devices and Methods of Use Thereof
  • 11,857,001; Antipathogenic Face Mask

The significance of the six mentioned patents lies in their innovative approaches towards utilizing silicon nitride (Si3N4) in a wide range of antipathogenic solutions. The surface antipathogenic properties of silicon nitride have been published extensively in the peer literature by SINTX as well as by outside investigators.

The first two patents (US Patent Nos. 11,591,217 and 11,672,252) cover slurries and composites of silicon nitride with polymethyl methacrylate (PMMA) for use in combating fungal infections in plants and preventing fungal colonization of medical implants - including specific applications in dentistry. The third patent (US Patent No. 11,738,122) describes implants comprised of polymeric and titanium materials coated with SiYAlON (a subclass of silicon nitride materials) as well as implants made from composites of SiYAlON and polymers like polyetheretherketone (PEEK) as candidates for reducing infection burden in biomedical applications. (These coating and composite technologies are the foundation for recent and ongoing NIH-funded commercialization work at SINTX.) The fourth patent (US Patent No. 11,844,344) presents a method for rapid inactivation of viruses using silicon nitride in various objects such as protective gear used by medical personnel. The fifth patent (US Patent No. 11,850,214) extends the antiviral composition to include various silicon nitride materials, thereby offering versatility in forms like slurry or spray applicable to medical devices. The final patent (US Patent No. 11,857,001) emphasizes an antipathogenic face mask containing silicon nitride and capable of inactivating human viruses.

The Company announced it has also received three foreign patents on its proprietary technologies in 2023. SINTX has forty-three patent applications that are currently pending around the world including in the United States, Asia, Europe, and Brazil.

“These patent grants and pending patent applications reflect SINTX’s commitment to protecting the intellectual property that has been created by the SINTX Research and Development team”, said Dr. Ryan Bock, VP of R&D. “Together, these patents showcase a wide range of innovative applications of silicon nitride in addressing diverse pathogenic challenges across various applications in agriculture, dentistry, medical implants, durable medical equipment, and personal protective equipment. We look forward to working with our current and future partners in commercializing these technologies and broadening the applications that benefit from silicon nitride.”

###

About SINTX Technologies, Inc.

SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. The Company has manufacturing and R&D facilities in Utah and Maryland.

For more information on SINTX Technologies or its materials platform, visit www.sintx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA), including, but not limited to, statements regarding SINTX’s ability to effectively develop a range of innovative applications of our silicon nitride formulations, SINTX’s ability to commercialize its technologies and broaden the applications that benefit from silicon nitride, and other statements that are not based on historical fact. Such forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from current expectations. Risks and uncertainties that may cause such differences include, among other things: SINTX’s products may not prove to be as effective as other products currently being commercialized or to be commercialized in the future by competitors; risks inherent in manufacturing and scaling up to commercial quantities while maintaining quality controls and qualification standards; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of SINTX’s products once commercialized; risks related to manufacturing products and market acceptance volatility in the price of SINTX’s common stock; SINTX’s ability to raise funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 29, 2023, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Business and Media Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com


FAQ

What is the significance of the patents granted to SINTX Technologies, Inc. (SINT)?

The patents are related to the antipathogenic properties of silicon nitride and cover a wide range of innovative applications in agriculture, dentistry, medical implants, durable medical equipment, and personal protective equipment.

How many patents has SINTX Technologies, Inc. (SINT) been granted in the last year?

SINTX has been granted its sixth United States patent in the last year, all related to the antipathogenic properties of silicon nitride.

What are the specific applications covered by the patents granted to SINTX Technologies, Inc. (SINT)?

The patents cover applications in agriculture, dentistry, medical implants, durable medical equipment, and personal protective equipment.

What are the future plans for commercializing the patented technologies by SINTX Technologies, Inc. (SINT)?

SINTX plans to work with current and future partners in commercializing these technologies and broadening the applications that benefit from silicon nitride.

Sintx Technologies, Inc.

NASDAQ:SINT

SINT Rankings

SINT Latest News

SINT Stock Data

11.20M
22.68M
8.82%
1.88%
2.39%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SALT LAKE CITY

About SINT

amedica is the only manufacturer of medical grade silicon nitride, an innovative biomaterial technology ideal for use in spinal fusion and across a variety of medical applications. our silicon nitride features a unique nanosurface texture that promotes bone growth and addresses clinical needs by providing excellent imaging capabilities and demonstrating antibacterial characteristics. our interbody fusion devices and pedicle screw systems are designed to benefit both the patient and the surgeon. with the only fda registered and iso 1345 certified silicon nitride medical device manufacturing facility in the world and a strong sales and distribution organization, we are committed to providing innovative healthcare solutions that improve patient quality of life.